MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2017 International Congress

    Impulse control disorder and associated clinical factors in drug-naïve Parkinson’s disease.

    D. Gupta, M. Marano, S. Fahn (New York, NY, USA)

    Objective: To investigate various clinical factors associated with Impulse Control Disorders (ICD) in Parkinson's disease (PD) patients who have never been exposed to Dopamine Replacement…
  • 2017 International Congress

    Dream content in Parkinson’s Disease

    V. Malgrati, F. Mancini, L. Manfredi, M. Lacerenza, A. Maggiolini (Milan, Italy)

    Objective: The aim of this observational study is to perform an analysis of dream characteristics in a large sample of Parkinson's Disease (PD) patients and…
  • 2017 International Congress

    Relationship between neuropsychological functioning and subjective measures of sleep quality in Parkinson Disease

    E. Montanaro, M. Zibetti, F. Dematteis, L. Lopiano (Torino, Italy)

    Objective: To analyze the relationship between subjectively reported sleep alterations and cognitive functions in a large series of advanced Parkinson Disease (PD) patients evaluated with…
  • 2017 International Congress

    Olfactory dysfunction in patient of Scans Without Evidence of Dopaminergic Deficit with parkinsonian bradykinesia

    S.J. Kang, J.Y. Ahn, H.-T. Kim (Seoul, Republic of Korea)

    Objective: To investigate the differences of olfactory dysfunction in patients within SWEDDs  Background: The concept of SWEDD(scans without evidence of dopaminergic deficit) originates from the clinical…
  • 2017 International Congress

    Clinical correlates of severe somnolence in Parkinson’s disease: results from an international naturalistic non-motor symptoms cohort

    R. Taddei, A. Sauerbier, M. Qamar, K. Ray Chaudhuri (London, United Kingdom)

    Objective: To compare patients with mild and severe daytime somnolence using cut-off values from item 15 of the Parkinson’s disease (PD) sleep scale (PDSS). Background:…
  • 2017 International Congress

    Parkinson’s disease and progressive dysphagia – consider myasthenia gravis

    P. Urban (Hamburg, Germany)

    Objective: We report on three consecutive patients with Parkinson’s disease, in whom myasthenia gravis turned out responsible for progressive dysphagia. Background: Swallowing dysfunction is common…
  • 2017 International Congress

    The utility of post-void residual volume versus sphincter electromyography to distinguish between multiple system atrophy and Parkinson’s disease

    T. Yamamoto, M. Asahina, Y. Yamanaka, T. Uchiyama, S. Hirano, M. Fuse, Y. Koga, R. Sakakibara, S. Kuwabara (Chiba, Japan)

    Objective:  To determine the ability of sphincter electromyography (EMG) and post-void residual urine volume (PVR) during a free-flow study and a pressure-flow study (PFS) for…
  • 2017 International Congress

    Gait characteristics in Atypical Parkinsonism

    S. Radovanovic, M. Jecmenica-Lukic, I. Petrovic, N. Dragasevic-Miskovic, M. Svetel, V. Kostic (Belgrade, Serbia)

    Objective: We investigated gait characteristics of progressive supranuclear palsy (PSP) and multiple system atrophy (MSA), with the aim to elucidate relatively specific disease differences in…
  • 2017 International Congress

    The environmental and genetic risk factors in multiple system atrophy in a Taiwanese population

    M.-C. Kuo, Y.-C. Lu, M.-L. Chen, C.-H. Tai, C.-H. Lin, R.-M. Wu (Taipei, Taiwan)

    Objective: The etiology of MSA remains uncertain. Cholesterol and its metabolism derangements, α-Synuclein and CoQ2 genetic polymorphism have been disclosed to be associated with the…
  • 2017 International Congress

    Rolipram, a PDE-IV inhibitor protects against experimental Parkinsonism in mice

    N. KUMAR, R. Khanna (Jaipur, India)

    Objective: Rolipram, a specific inhibitor of the phosphodiesterase IV (PDE IV), has recently been shown to exert neuroprotective effects in an Alzheimer transgenic mouse model…
  • « Previous Page
  • 1
  • …
  • 77
  • 78
  • 79
  • 80
  • 81
  • …
  • 155
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
    • DaTscan in clinical evaluation of Multiple System Atrophy
    • Effect of marijuana on Essential Tremor: A case report
    • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
    • Patients with Essential Tremor Live Longer than their Relatives
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley